Category: M2BIO

CAPE TOWN, SA / ACCESSWIRE / December 30, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:

The Company is pleased to announce a private placement financing of $450,000.00 USD with ThreeD Capital Inc. In consideration, the Company will issue 1,500,000 units (the “Units”) at a price of $0.30 per Unit. Each Unit will consist of one (1) common share of the Corporation (a “Common Share”) and one Common Share purchase warrant (a “Warrant”) exercisable at $0.30 per Warrant. The Warrants will expire three (3) years from the date of issuance. At the option of the Company, the Company may force the Holder to exercise the Warrant at a price per share equal to $0.30, provided that (i) the average closing bid price of the Company’s Common Stock as reported by the OTC Bulletin board shall have been equal to or greater than $1.00 for a period of twenty (20) consecutive trading days ending on the date preceding the date on which the Holder receives a notice from the Company in which it announces its intention to force the exercise of the Warrants. The closing date for the Private Placement will be at the latest January 30, 2021.

“Enchanted to have Sheldon Inwentash and his company ThreeD Capital aboard as our first strategic investor. Much more to come on this very synergistic alliance in the coming weeks” said Jeff Robinson, CEO of Wuhan General Group.

About ThreeD Capital Inc.
ThreeD (IDK)(IDKFF), is a publicly?traded Canadian?based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.

For further information:
Website: https://threedcapital.com
Follow us on Twitter: https://twitter.com/home
Follow us on LinkedIn: https://www.linkedin.com/feed/

Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary: Feldman@threedcap.com
Phone: 416?941?8900 ext 106

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M₂bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:
Publicly traded company (OTC PINK:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc

View source version on accesswire.com:
https://www.accesswire.com/622584/Wuhan-General-Group-Announces-450000-USD-Private-Placement-by-ThreeD-Capital-Inc

CAPE TOWN, SA / ACCESSWIRE / December 23, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:

The Company is pleased to inform its shareholders that it is positioning itself in the rapidly expanding hemp industry by launching the M2BIO Hemp Product Research and Development Division to be based in Cape Town, South Africa.

The M2BIO Hemp Division will be led by Willem Jonker, COO of Wuhan General Group. He will oversee a team of remarkable engineers spanning multiple engineering disciplines. “Hemp is destined to have a colossal impact on the world in so many positive ways. We are keyed up to be at the forefront of research into how to turn stalks into products. This is the next logical phase in our quest to bring the world the benefits of the miracle plant.” said Willem Jonker, COO of Wuhan General Group.

Wuhan General Group CEO Jeff Robinson added: “It is our responsibility to do our part in helping the environment and the safety of future generations by exploring sustainable alternatives and acting responsibly. The packaging possibilities and opportunities of hemp are absolutely awesome. Our first new team members are locked and loaded!”

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M₂bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE:  Wuhan General Group, Inc./M₂Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/622164/Wuhan-General-Group-Launches-Hemp-Product-Research-Development-Division

CAPE TOWN, SA / ACCESSWIRE / December 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:

The research team funded by Wuhan General Group has successfully published a second paper on psychedelic science. This paper is entitled “Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes” and has been released on the Nature Research platform. (the first published paper can be found here)

The following is an excerpt from the newly published study: “Study investigates the effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushrooms use from genus Psilocybe and Panaeolus respectively, in a pathological hypertrophy conditions in which endothelin-1 disorder is a contributor to pathogenesis. Results proposed that the water extracts of Panaeolus cyanescens and Psilocybe cubensis did not aggravate the pathological hypertrophy induced by endothelin-1 and also protected against the TNF-α-induced injury and cell death in concentrations used. Results support medicinal safe use of mushrooms under controlled conditions and cautioned use of higher concentrations. ”

“This is another great milestone for the company as the findings are very significant to psychedelic research. The research team led by Sanah M. Nkadimeng is making a lot of notable progress in bringing psychedelics to the forefront of medicine. Stay tuned, so much more exciting and useful science to share very soon,” said Wuhan General Group CEO Jeff Robinson.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M₂bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M₂Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/621814/Wuhan-General-Group-Updates-on-Second-Scientific-Paper-Published-on-Psychedelics

CAPE TOWN, SA / ACCESSWIRE / December 18, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:

The Company is set to expand into the European market with its recently launched Medspresso™ line of CBD infused hot beverages. Medspresso™ is a premium functional beverages brand that encompasses a current product line of CBD-infused African coffees, teas and hot chocolates. The recent launch in early November has drummed up numerous inquiries from around the globe. The company is planning to ship its first international order to Cafféluxe Limited International in January 2021.

Michael Sachar, Cafféluxe Commercial Director said: “The interest has been nothing short of phenomenal. We will move the Medspresso™ range through existing distributors in the UK, Europe and GCC countries (Middle East). ”

The company is scaling up its production to meet the growing demand. Currently, the products are available at the Cafféluxe showroom and E-commerce websites across South Africa.

“The market response for Medspresso™ has been nothing short of spectacular. Consumers are loving the products and the brand. We will always work as hard as we can to earn and keep the loyalty of our consumers by delivering exceptional products far beyond expectations. ” said Wuhan General Group CEO Jeff Robinson.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M₂bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is listed and traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group, Inc./M₂Bio Sciences, Inc

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/621529/Wuhan-General-Group-Expands-into-UK-Market-with-Medspresso

CAPE TOWN, SA / ACCESSWIRE / December 4, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update to its shareholders:

The Company is pleased to inform its shareholders that with OTCIQ having just granted access to the platform, it has started the process of updating its profile on OTCMarket. In addition, the Company is planning to post financials and information disclosure in the coming weeks. Our filings are currently being prepared and we anticipate all filings to be uploaded by December 8th. Once OTCMarket has reviewed our filings and approved them by moving us to Limited Information, we will proceed to file and upload the required opinion letter and have Current Information status tier by mid-December.

“This is a big first step in a series of very important milestones for Wuhan. Having a Current Status allows for much greater flexibility enabling us to execute some rather nifty deliverables.” said Jeff Robinson, CEO of Wuhan General Group.

Our filings can be viewed on OTC Market’ s website at the following link: https://www.otcmarkets.com/stock/WUHN/disclosure.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M₂Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M₂Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/619511/Wuhan-General-Group-Financials-Update

CAPE TOWN, SA / ACCESSWIRE / November 2, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update on its Medspresso and Handcrafted Delights brands:

The Launch Announcement

The launch of Medspresso and Handcrafted Delights will be celebrated November 7th, 2020 at our partner, Caffeluxe‘s showroom, in Cape Town, South Africa. The event will include free tastings of the entire premium product range, consisting of CBD-infused African coffee, Rooibos tea, decadent Ivory Coast hot chocolate and delectable guilt-free cookies. There will also be interesting competitions with great hampers, vouchers and prizes up for grabs to start off the journey on a high note!

“We are excited to see the reactions and get most valuable feedback from our future customers. We are very confident they will absolutely love them and appreciate the care and quality with which they are produced. Nothing but the very best for our customers!” said Wuhan General Group CEO, Jeff Robinson.

The event will be open to all and specifically those interested in learning about the miraculous world of CBD. Customers will be able to treat themselves to 4 CBD-infused beverages and 10 mouthwatering CBD cookies like the Matcha White Chocolate Chip, Lavender and Fynbos Honey Shortbread and the Dark Ivory Coast Chocolate Macaron Cookie. RSVP to the event here. The entire line will be available for purchase here: Medspresso E-Commerce website.

“It has been quite the expedition in getting these 2 lines ready for launch with Covid-19 and all the supply chain issues. The team has put in so much hard work and I’m so very proud of all of the members,” added Wuhan General Group CMO, Dr. Anna Morera Leralta.

The combined launch of Medspresso and Handcrafted Delights is highly anticipated. It is a major milestone for Wuhan and the timing is perfect with the ranges being available just in time for the holiday season.

‘’We are thrilled to see these two very unique brands available for sale at our showroom and online. Inquiries about Medspresso have been very robust across Africa and internationally,” said Michael Sachar, Commercial Director of CaffeLuxe.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M₂Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/613872/Wuhan-General-Group-Announces-Medspresso-Handcrafted-Delights-Launch-Event-in-Cape-Town

CAPE TOWN, SA / ACCESSWIRE / October 26, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its Medspresso brand:

The company is pleased to announce the upcoming product launch of “Handcrafted Delights” by Medspresso^TM. The new line entails medical-grade organic CBD infused treats made with top-shelf natural and organic ingredients ethically sourced from across Africa.

The Company’s mission these past few months was to design, formulate and bring to light, healthy and exceptional substitutes for guilty pleasures under this new sub-brand “Handcrafted Delights“.

This novel brand kicks-off with a range of unique, scrumptious and healthy cookies that will do justice to the tagline “The Good Kind of Guilty“. As good as coffee and cookies are together, this is just the beginning of many more CBD infused products currently under development by the “Foodicine team”.

This new brand will treat you with an initial 10 moreish cookies that are listed below. Each with the common benefits like reducing pain, boosting energy, relieving stress, providing antioxidants, and improving immunity. In addition, an assortment of vegan options is available:

• Matcha & white choc chip
  • Benefits: boosts physical energy and brain function, and supports weight-loss.
• Rooibos matcha & white choc chip (caffeine-free)
  • Benefits: Bone strengthening minerals, boosts brain function and supports weight-loss.
• Dark choc macaron cookie
  • Benefits: Rich in vitamins and nutrients, lowers cholesterol and bone strengthening minerals
• Chocolate crinkle cookie (Vegan)
  • Benefits: Rich in nutrients and polyphenols that improve blood flow to the brain
• Blueberry crinkle cookie (Vegan)
  • Benefits: Rich in nutrients and antioxidants
• Ginger & molasses (Vegan)
  • Benefits: Bone strengthening minerals, immune boosting, anti-inflammatory
• Turmeric & agave (Vegan)
  • Benefits: Low glycemic index, immune boosting, anti-inflammatory
• Rosewater & chamomile shortbread
  • Benefits: Helps with sleep, reduces inflammation, mood enhancer
• Cappuccino shortbread
  • Benefits: Increases focus, boosts physical energy
• Lavender & honey shortbread
  • Benefits: Helps with sleep, relaxing, rich in nutrients

*Benefits will vary from person to person.
*Each cookie will contain 5mg of medical-grade organic CBD.

All of our Handcrafted Delights will be available for sale on the Medspresso E-Commerce website medspresso.co very soon. You may subscribe to our newsletter to get timely updates and upcoming promotions.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M₂Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc

View source version on accesswire.com:
https://www.accesswire.com/612242/Medspresso-Launches-Handcrafted-Delights-CBD-Infused-Functional-Foods

CAPE TOWN, SA / ACCESSWIRE / October 5, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share today the appointment of Mr. Willem Jonker, CA(SA), as Chief Operating Officer of the Cannabis Cultivation Project effective immediately.

Willem is an experienced leader and a recognized international authority in the cannabis industry. He is most often referred to as the grandfather of medicinal cannabis in Africa.

Willem is a chartered accountant and formerly a senior partner at Allan Gray, the largest independent investment manager in South Africa. In 1999, he started and/or expanded four small asset management businesses throughout Southern Africa. In the process, he moved into the field of private equity, with a focus on telecommunications (telecoms licenses in the Democratic Republic of Congo, South Africa and Tanzania), energy (hydrogen, solar, “green” cement substitute, and low-energy lights), real estate (two large shopping centers among others), commodity trading and project finance (development finance institutions and equity and debt finance).

Since 2015, Willem has been building Medigrow Africa into the largest portfolio of licensed medicinal cannabis companies in Africa. Medigrow Africa’s mission is to give as many people as possible access to cannabis as a medicine.

“We are very pleased to welcome Mr. Willem Jonker to the Wuhan team,” commented Jeff Robinson, Chairman & CEO of Wuhan, “As COO, he will oversee all aspects of the Company’s cannabis business operations. His strong track record in operational management and financial engineering will make for a great addition to our executive team.”

“His ability to align project requirements and capital has been key in mounting such an impressive portfolio for Medigrow. Willem will leverage this strength across our Tsime project and other potential future acquisitions.”

“For me it is a great opportunity to bring Wuhan’s vision to life in a leadership role as COO,” said Willem. “My focus will be to support and implement Jeff’s strategic vision of developing and strengthening the Wuhan position and reputation as the plant-based cannabinoids biotech leader for the next decade.”

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M₂Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/609109/Wuhan-General-Group-Appoints-Willem-Jonker-as-Chief-Operating-Officer

CAPE TOWN, SA / ACCESSWIRE / September 22, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share the following corporate updates:

Tsime Pharmaceuticals

The last step in completing the due diligence regarding the acquisition of Tsime Pharmaceuticals Inc. (“Tsime”) was accomplished last week with the visit to the Tsime property in Lesotho. Based on our positive results, the Company is pleased to announce it is going forward with the acquisition of Tsime Pharmaceuticals and the plans to cultivate up to 3 hectares of medicinal-grade cannabis on the farm with a land area covering 23 hectares (57 acres). With its license, the Company will grow, extract and process medicinal cannabis on-site, a key element in driving research and the manufacturing of cannabidiol (CBD) by-products. The project’s first crop is scheduled for Q2-Q3 2021, with projected annual revenue of USD 9.8 Million.

We are also very pleased to announce that Willem Jonker, head of the cannabis operation Medigrow will be joining the Wuhan team as Chief Operating Officer in the coming days. A future press release will be shared on the subject once effective.

As well, Bataung Likate has been appointed as the onsite Director of Tsime Pharmaceuticals.

Batung Likate, Director of Tsime, said: “We at Tsime Pharmaceuticals, together with the Chief and the local community of which we form part, are excited that this project is coming to fruition. This area otherwise has few formal employment opportunities, so we welcome M2Bio Sciences with open arms.”

Information regarding the closing of the transaction will be announced in due course.

Capital requirement?

The total project requirement for the first year is USD 4.7 million consisting of USD 2.82 million in Capital Expenditures and Operating Costs of USD 1.88 million.

The Company is actively discussing with private and public financial organizations on the potential funding opportunities and financial instruments to be deployed to secure the necessary capital.

Some key milestones are the construction of the greenhouses (18 tunnels equivalent to 5,400 square metres), establishing Security Protocols and starting the first cultivation.

The company expects to have the first harvest 9 months from the day it breaks ground.

How profitable is a cannabis cultivation operation?

Based on revenue projections for the first 0.5-hectare facility, the net income before tax is USD 9.82 million. After deducting yearly operating expenses, a projected net profit of USD 6.37 million could be realized. The applicable tax rate in Lesotho is 10% for agriculture.

Projected net income after tax is $5.73 million per year.

The Company is currently in discussions with interested parties for the purchase of future cannabis production.

“I enjoyed our trip to Lesotho on both a personal and business level. Willem shared so much remarkable and indispensable knowledge and wisdom. We have such an unfair IP advantage in knowing what has worked and what hasn’t for those that ventured ahead of us. We thank the early players for laying the foundation. It is our turn to sow the seeds and reap the bountiful rewards for our shareholders. “said Wuhan CEO, Jeff Robinson.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M₂Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/607242/Wuhan-General-Group-Corporate-Update-on-Tsime-Pharmaceuticals-Acquisition

CAPE TOWN, SA / ACCESSWIRE / August 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share the following corporate update:

Supply Chain, Operations and Covid-19:

August 18th, South Africa transitioned from level 3 lockdown to level 2 with many restrictions being lifted amid its battle with coronavirus. This is great news for the Company and the country, as it enables more flexibility in managing supply chain risk and disruption. Coronavirus has had a colossal impact on almost all businesses in South Africa and around the world where supply chain challenges were felt from the global spread of COVID-19. With many restrictions being lifted, conditions should approach normalcy in the coming months.

Visits:

Wuhan CEO Jeff Robinson and Willem Jonker, Head of Wuhan Cannabis Production are scheduling a visit to the Tsime Pharmaceuticals site in Lesotho where the Company will cultivate 3 hectares of medicinal grade cannabis on a farm with a land area covering 32 hectares (or 80 acres). With its license, the Company will grow, extract and process medicinal cannabis on-site, a key element in driving Wuhan’s medicinal cannabis research and the manufacturing of CBD by-products. Both Mr. Robinson and Mr. Jonker will be tested for Coronavirus and will need to test negative in order to make the 4-hour flight to the Kingdom of Lesotho from Cape Town.

Mr. Robinson and other Wuhan team members visited Edelweiss Laboratories on August 19th to finalize updated and go-to-market formulations for Dr. AnnaRx^tm Skincare, Haircare and Oral care Lines.

Mr. Robinson is scheduled to visit the beverage manufacturing partner CaffeLuxe in the coming weeks to place their first significant order for the Medspresso^TM range for sale through online e-commerce and select retail outlets.

Sales:

The company has been selling its Medspresso^TM Tanzanian Peaberry CBD Coffee online in Cape Town. Customer feedback has been extremely positive.

New Corporate Website:

The company is launching a brand new revamped website under the newly created corporate name M2Bio Science. The website offers quick and easy access to essential information and offers a more comprehensive understanding of the Company’s vision, products and innovations. The website also has an extensive investor section with updated company news and events, financial and stock information, filings and corporate governance information. The new website is located at the new address: https://m2bio.co

YouTube Channel:

Please visit the M2Bio Sciences YouTube channel. The Company is using the following platform for business communication and to improve and augment their public relations efforts. Here are some elements posted and many more to come in the near future.

• Product videos
• Trade and industry videos
• Company executive interview videos
• New partnership videos

‘’Coronavirus slowed everybody down without a doubt. It did however give us lots of time to reflect, improve and plan much more efficiently and effectively. I look forward to sharing a boatload of rousing news in the near-term including our work to date in the psychedelics space. Stay tuned, we’re just getting started!”

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M₂Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: https://m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/M2BIO

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/602764/Wuhan-General-Group-Corporate-Update